HOUSTON, October 6, 2011 - - Firm continues to strengthen its Energy Trading and Risk Management services for European clients
BERLIN, October 6, 2011 - OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan™, from Novartis Pharma AG.
Older News
S M T W T F S
30 31 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
Copyright© 2011 The Gaea Times